Home » Pipeline
Pipeline
January 19, 2020
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Alucent Biomedical | Natural Vascular Scaffolding technology | peripheral artery disease | phase 1 trial enrolling up to 15 patients across five U.S. research sites |
| Clover Biopharmaceuticals | SCB-313 | malignant pleural effusions | phase 1 trial dosing first patient in China |
| Tmunity | CART-TnMUC1-01 | TnMUC1-positive advanced cancers | phase 1 trial dosing first patient |
| Cellectis | UCART123 | relapsed/refractory acute myeloid leukemia (AML) | phase 1 trial dosing first patient |
| BioTheryX | BTX-A51 | relapsed/refractory AML | phase 1 initiation of patient dosing |
| Innovation Pharmaceuticals | Brilacidin | ulcerative colitis | phase 1 dosing of first cohort of 3 patients |
| Retrotope | RT001 | Friedreich’s ataxia | phase 2/3 trial dosing of first patient |
| Zymeworks | ZW25 | locally advanced and/or metastatic HER2-positive, HR-positive breast cancer | phase 2 trial initiated, enrolling up to 76 patients in the U.S. and Canada |
| Hutchison China MediTech | surufatinib | advanced solid tumors | phase 2 trial initiated in China |
| Akero Therapeutics | AKR-001 | non-alcoholic steatohepatitis | ongoing phase 2a trial expanded to include patients with compensated cirrhosis |
| Tolero Pharmaceuticals | Alvocidib | AML | phase 2 trial first patient dosed |
| Tyme Technologies | SM-88 (racemetyrosine) | high-risk sarcomas | phase 2 trial first patient dosed |
| Neuroptika | NRO-1 | dry eye disease | phase 2 trial first patient enrolled of 120 patients |
| ContraFect | exebacase | Staph aureus bacteremia | phase 3 trial first patient dosed, 350 patients |
| Akcea Therapeutics Ionis Pharmaceuticals |
AKCEA-TTR-LRx | transthyretin-mediated amyloid cardiomyopathy | phase 3 trial initiated |
| Abeona Therapeutics | EB-101 | recessive dystrophic epidermolysis bullosa | phase 3 trial initiated, assessing up to 15 patients |
| Cerevel Therapeutics | tavapadon | Parkinson’s disease | Phase 3 trial initiated, enrolling 1,200 patients |
| Novavax | NanoFlu | influenza in older adults | Fast-Track designation granted by the FDA |
| Arena Pharmaceuticals | APD418 | decompensated heart failure | Fast-Track designation granted by the FDA |
| Presage Biosciences | CIVO Technology Platform | cancer | IND approved by the FDA |
| Lannett Company | cocaine hydrochloride nasal solution | local anesthetic | NDA approved by the FDA |
| Novo Nordisk | Ozempic (semaglutide) | cardiovascular events in diabetes patients | approved by the FDA for additional indication |
| Neurelis | Valtoco (diazepam) nasal spray | intermittent, stereotypic episodes of frequent seizure activity | approved by the FDA |
Upcoming Events
-
28Sep
-
12Oct
-
18Oct
-
16Nov
